Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaRue, H
Right arrow Articles by Fradet, Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaRue, H
Right arrow Articles by Fradet, Y

Clinical Cancer Research, Vol 1, Issue 4 435-440, Copyright © 1995 by American Association for Cancer Research


Human papillomavirus in transitional cell carcinoma of the urinary bladder

H LaRue, M Simoneau and Y Fradet
Centre de Recherche en Cancerologie de l'Universite Laval, L'Hotel-Dieu de Quebec, 11 cote du Palais, Quebec G1R 2J6, Canada.

The presence of human papillomavirus (HPV) was detected in transitional cell carcinoma of the urinary bladder. PCR amplification of DNA from 71 tumors, using consensus primers for a fragment of the L1 gene, detected 6 strongly positive tumors (through ethidium bromide staining of a gel) and 22 moderately positive tumors (through Southern blotting of the amplified DNA) for a total of 28 (39%) of the tumors. The presence of HPV was correlated with grade but not stage of the tumors. Typing of HPV was performed on 31 tumors: all positive tumors contained HPV 16 DNA except for one Ta tumor which contained HPV 11 DNA. Our data also showed a large variability in the sensitivity of HPV DNA detection, depending on sample fixation, DNA preparation, and amplification conditions, which may explain in large part the discrepancies reported in the literature on the association of HPV to bladder cancer. Because of the low HPV DNA copy number observed in bladder tumors, our results suggest that HPV should ideally be tested on fresh or frozen tumor material, that SDS detergent should be avoided for the preparation of DNA, and that the amplification conditions are critical for optimal detection.


This article has been cited by other articles:


Home page
CarcinogenesisHome page
H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers
Carcinogenesis, January 1, 2000; 21(1): 101 - 106.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
I. Orlow, H. LaRue, I. Osman, L. Lacombe, L. Moore, F. Rabbani, F. Meyer, Y. Fradet, and C. Cordon-Cardo
Deletions of the INK4A Gene in Superficial Bladder Tumors : Association with Recurrence
Am. J. Pathol., July 1, 1999; 155(1): 105 - 113.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.